Summary of Jan. 2024 Drug Utilization Review Board Meeting Now Available

Published on

The Texas Drug Utilization Review Board met Friday, Jan. 26, 2024, to recommend clinical prior authorizations and drugs on the Texas Medicaid Preferred Drug List. Available online are:

  • A recording of this meeting’s webcast
  • A report of this quarter’s clinical prior authorization and PDL recommendations
  • Approved minutes from the Thursday, Oct. 12, and Friday, Oct. 13, 2023, meetings
  • The PDL drug class review schedule for the Friday, April 26 meeting

Clinical Prior Authorization Updates

Clinical prior authorizations may implement for traditional Medicaid and managed care at any time:

  • Providers and stakeholders will be notified once an implementation date has been set for traditional Medicaid.
  • Refer to MCO Search for a link to each MCO’s clinical prior authorization page.
  • The Pharmacy Clinical Prior Authorization Assistance Chart identifies which prior authorizations are utilized by each MCO and how those relate to those used by HHSC.


Approved as presented:

Not approved as presented:

Preferred Drug List Updates

Preferred drugs are medications recommended by the board for their efficaciousness, clinical significance, safety, and cost effectiveness. PDL recommendations are pending until the final decision is released by the Texas HHS executive commissioner. HHSC will incorporate the approved decisions from the Oct. 2023 board meetings into the Jan. 2024 PDL. MCOs have the same non-preferred prior authorization criteria requirements from following the Texas formulary and PDL.

The Oct. 2023 PDL recommendations are available. Notable changes include:

PDL ClassDrugCurrent PDL StatusRecommended Status
Acne Agents, TopicalAdapalene gel OTC (topical)Non-PreferredPreferred
Acne Agents, TopicalCabtreo gel (topical)Non-ReviewedPreferred
Acne Agents, TopicalZMA Clear Cleanser (topical)Non-ReviewedPreferred
Analgestics, Narcotics LongTramadol ER (Ryzolt) (oral)PreferredNon-Preferred
Bladder Relaxant PreparationsVesicare (oral)PreferredNon-Preferred
Glucagon AgentsGvoke Pen (subcutaneous)PreferredNon-Preferred
Glucagon AgentsZegalogue Autoinjector (subcutaneous)Non-PreferredPreferred
Movement Disorders

Austedo XR (oral)

Austedo XR (oral)

Movement DisordersTetrabenazine (oral)Non-PreferredPreferred
Movement DisordersXenazine (oral)PreferredNon-Preferred
Neuropathic PainDermacinrx Lidocan patch (topical)Non-ReviewedNon-Preferred
Neuropathic Pain

Lidocaine (AG) (topical)

Lidocaine (topical)

Neuropathic PainLidocan II (topical)Non-ReviewedNon-Preferred
Neuropathic PainXyliderm (topical)Non-ReviewedNon-Preferred
Oncology, Oral – LungAugtyro capsule (oral)Non-ReviewedPreferred
Oncology, Oral – LungRozlytrek pellet pack (oral)Non-ReviewedPreferred
Oncology, Oral – LungXalkori pellet (oral)Non-ReviewedPreferred
PAH Agents, oral and inhaledLiqrev Suspension (oral)Non-ReviewedNon-Preferred
PAH Agents, oral and inhaledOrenitram Titration Kit (oral)Non-ReviewedNon-Preferred
Phosphate BindersXphozah tablet (oral)Non-ReviewedNon-Preferred
Stimulants and Related AgentsQelbree (oral)Non-PreferredPreferred
Stimulants and Related AgentsRelexxii (oral)Non-ReviewedNon-Preferred
AnticonvulsantsMotpoly XR (oral)Not ReviewedPreferred
Opiate Dependence TreatmentsNarcan Spray OTC (Nasal)Not ReviewedPreferred
AntipsychoticsRykindo (intramusc)Not ReviewedNon-Preferred
Cytokine and CAM AntagonistsAdalimumab-Adbm Kit (Injection) (Cf) 50 Mg/MlNot ReviewedNon-Preferred
Cytokine and CAM AntagonistsAdalimumab-Adbm Pen Kit (Injection) (Cf) 50 Mg/MlNot ReviewedNon-Preferred
Cytokine and CAM AntagonistsEntyvio Pen (Subcutane)Not ReviewedNon-Preferred
Erythropoiesis Stimulating ProteinsJesduvroq Tablet (oral)Not ReviewedNon-Preferred
Glucocorticoids, InhaledAirsupra Hfa (Inhalation)Not ReviewedNon-Preferred

About the Texas DUR Board

Board members meet quarterly in Austin to make recommendations about outpatient prescription drugs in the Medicaid program. The schedule of upcoming meetings, instructions on how to submit written materials to the board, and directions about publicly testifying before the board are available on the VDP website.